CREDENCE
2019
Canagliflozin and Renal Events in Diabetes with Established Nephropathy
In 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.
Result
Efficacy: ESKD, doubling of creatinine, or renal or CV deathHR 0.70 (95% CI 0.59-0.82) · P < 0.001
Below 1 favours canagliflozin, above 1 favours placebo.
Also reported: Heart-failure hospitalisation HR 0.61.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT, stopped early
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Also listed in
- Diabetes & cardiometabolic
- Source
- Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306.doi 10.1056/NEJMoa1811744
Discussion & critique
First dedicated SGLT2-inhibitor renal-outcome trial; stopped early for efficacy. Limited to T2DM with macroalbuminuria.